Palvella Therapeutics (PVLA) Capital Expenditures (2014 - 2023)
Palvella Therapeutics (PVLA) posted quarterly Capital Expenditures of -$13000.0 for Q4 2023, down 101.29% year-over-year from $1.0 million in Q4 2022, and down 118.84% quarter-over-quarter from $69000.0 in Q3 2023.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Capital Expenditures (2014 - 2023) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Capital Expenditures for 10 consecutive years, with -$13000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Capital Expenditures fell 101.29% year-over-year to -$13000.0; the TTM figure through Sep 2024 stood at -$13000.0 (down 101.09% YoY), while the FY2023 annual figure was $171000.0, down 83.57% from the prior year.
- Capital Expenditures retreated to -$13000.0 in Q4 2023 per PVLA's latest filing, from $69000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.9 million in Q1 2020 and bottomed at -$987000.0 in Q3 2022.
- Historically, Capital Expenditures has averaged $367450.0 across 5 years, with a median of $287000.0 in 2019.
- On a YoY basis, Capital Expenditures climbed as much as 1492.56% in 2020 and fell as far as 462.07% in 2020.
- Palvella Therapeutics' Capital Expenditures stood at $1.2 million in 2019, then sank by 50.85% to $578000.0 in 2020, then slumped by 40.83% to $342000.0 in 2021, then soared by 195.32% to $1.0 million in 2022, then sank by 101.29% to -$13000.0 in 2023.
- Business Quant data shows PVLA's Capital Expenditures at -$13000.0 in Q4 2023, $69000.0 in Q3 2023, and $67000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -13,000.00 |
| Sep 30, 2023 | 69,000.00 |
| Jun 30, 2023 | 67,000.00 |
| Mar 31, 2023 | 48,000.00 |
| Dec 31, 2022 | -11,000.00 |
| Sep 30, 2022 | 34,000.00 |
| Jun 30, 2022 | 629,000.00 |
| Mar 31, 2022 | 389,000.00 |
| Dec 31, 2021 | 342,000.00 |
| Sep 30, 2021 | 350,000.00 |
| Jun 30, 2021 | 229,000.00 |
| Mar 31, 2021 | 28,000.00 |
| Dec 31, 2020 | 578,000.00 |
| Sep 30, 2020 | -840,000.00 |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.93 Mn |
| Dec 31, 2019 | 1.18 Mn |
| Sep 30, 2019 | 232,000.00 |
| Jun 30, 2019 | 933,000.00 |
| Mar 31, 2019 | 121,000.00 |